secwatch.observer — SEC 8-K summary
======================================

Issuer:     Penumbra Inc (PEN)
CIK:        0001321732
Form:       8-K
Filed at:   2026-01-15T23:59:59+00:00
Accession:  0000950103-26-000523
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.01, 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boston Scientific to acquire Penumbra: $374 cash or 3.8721 BSX shares per share; 73% cash/27% stock
--------------------------------------------------------------------------------

- Penumbra holders elect $374 cash or 3.8721 BSX shares per share; proration targets 73.26% cash/26.74% stock.
- Termination: Penumbra pays $525M if it accepts superior offer; Boston Sci pays $900M if antitrust fails.
- Closing subject to Penumbra stockholder vote, HSR and foreign antitrust clearance, S-4 effectiveness, NYSE listing.
- Preliminary Q4/FY2025 results released; audited financials pending, specific figures not in filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1321732/000095010326000523/0000950103-26-000523-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1321732/000095010326000523/dp240008_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-26-000523

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer